FDA will expedite review of cancer drug Istodax for expanded use

02/28/2011 | Reuters

The FDA granted priority-review status to Celgene's Istodax for use in patients with peripheral T-cell lymphoma who have undergone prior treatment. The agency, which approved the drug for cutaneous T-cell lymphoma, is expected to decide by June 17 on the expanded use.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA